Global mRNA Synthesis and Manufacturing Market Overview

The mRNA synthesis and manufacturing market is estimated to be USD 0.56 billion in 2026. It is expected to reach USD 4.20 billion by 2035, representing a CAGR of 40.9% between 2028 and 2035.

mRNA Synthesis and Manufacturing Market Landscape

See What’s in the Full Report – Request Your Complimentary Insights!

Ribonucleic acid (RNA) is a molecule which is present in all living cells and translates genetic information to various proteins in order to perform several cellular processes. Notably, RNA can be of different types, including messenger RNA (mRNA), transfer RNA (tRNA) and ribosomal RNA (rRNA); of these, mRNA has emerged as one of the key therapeutic modalities in the modern healthcare industry.

mRNA is a single-stranded molecule, which carries the genetic information present in the DNA to produce proteins. The genetic coding which is present on mRNA gets translated into amino acids; these amino acids get further processed into a functional product (proteins).

mRNA Synthesis and Manufacturing Market List

mRNA Synthesis and Manufacturing Market Distribution by Type of Product Manufactured

mRNA Synthesis and Manufacturing Market Distribution by Kit Components

Notably, post COVID-19 pandemic, mRNA vaccine and therapeutics manufacturing have garnered significant attention as they have evolved as a next generation drug class for the treatment of COVID-19. Further, mRNA therapeutics are also being evaluated for the treatment of various oncological, infectious, and genetic disorders. This versatility and scalability of mRNA therapeutics have further contributed to their adoption, positioning them as a cornerstone of personalized mRNA medicine production and vaccine development. In addition, these therapeutics are likely to have an improved safety profiles for patients as there is minimal risk of insertional mutagenesis.

mRNA Synthesis and Manufacturing Market Distribution by Year of Partnership

mRNA Synthesis and Manufacturing Market Likely Partner Analysis

mRNA Synthesis and Manufacturing Market Big Player Initiatives

Owing to this success, the demand for mRNA synthesis and manufacturing has increased significantly, prompting mRNA therapeutic / vaccine developers to actively explore avenues that enable them to meet the existing demand. In this context, outsourcing emerged as a lucrative option for mRNA therapeutic / vaccine development companies, offering efficient and scalable solutions for mRNA therapeutics and vaccine development.

mRNA Synthesis and Manufacturing Market Trends and Outlook

mRNA Synthesis and Manufacturing Market Distribution by Geographical Region

mRNA Synthesis and Manufacturing Market Distribution by Indication Type

Considering the prevalent trends and projected opportunity associated within the overall mRNA synthesis and manufacturing domain, we believe that the domain is likely to witness single-digit market growth in the foreseen future.

mRNA Synthesis and Manufacturing Market: Report Attributes

Key Report Attributes	Details
Historical Trend	Since 2021
Forecast Period	Till 2035
Market Size 2026	$ 0.56 Billion
Market Size 2035	$ 4.20 Billion
CAGR (2028-2035)	40.9%

The mRNA synthesis and manufacturing market analysis also features the likely distribution of the current and forecasted opportunity within the mRNA synthesis and manufacturing domain across various segments, such as type of product, scale of operation, synthesis and manufacturing activity, indication type, therapeutic area, application area and geographical regions.

We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios represent different tracks of the industry's evolution.

The rising incidence of chronic diseases, increasing need for technical expertise in the domain and development of advanced mRNA technologies have spurred the need for outsourcing mRNA synthesis and manufacturing activities. Additionally, the use of artificial intelligence / AI in drug discovery has significantly helped the stakeholders to develop more accurate, treatment specific mRNAs for therapeutics and vaccines. Within this workflow, lipid CMO supplies specialist development and manufacturing capacity for lipids used in advanced formulations.

Recent Developments in mRNA Synthesis and Manufacturing Market

Several recent developments in the field of mRNA synthesis and manufacturing have occurred, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall mRNA synthesis and manufacturing market trends detailed in our analysis.

In July 2025, Wacker Chemie opened its new Wacker Biotechnology Center in Munich, Germany, to accelerate the development of biopharmaceutical manufacturing processes for proteins and nucleic acids.

In June 2025, Ethris entered into a collaboration with Thermo Fisher Scientific, combining the former company’s comprehensive mRNA technology platforms with Thermo Fisher’s manufacturing capabilities, with an aim to advance mRNA therapeutics from research to clinical stages.

In June 2025, TriLink BioTechnologies signed a partnership agreement with Quantoom Biosciences to access former company’s CleanCap® mRNA capping technology and accelerate the overall mRNA production processes.

mRNA Synthesis and Manufacturing Market Segmentation Insights

The market research report presents an in-depth analysis of the various mRNA synthesis and manufacturing companies, across different segments, as defined in the table below:

mRNA Synthesis and Manufacturing Market: Market Segmentation

Market Segmentation	Details
Type of Product	Active Pharmaceutical Ingredients Finished Dose Formulations
Scale of Operation	Preclinical and Clinical Scale Commercial Scale
Synthesis and Manufacturing Activity	Contract Manufacturing In-house Manufacturing
Indication Type	COVID Indications Non-COVID Indications
Therapeutic Area	Infectious Diseases Oncological Disorders Other Disorders
Application Area	mRNA Vaccines mRNA Therapeutics
Geographical Regions	North America Europe Asia-Pacific Latin America Middle East and North Africa
Market in North America	US Canada
Market in Europe	France Germany Italy Spain UK Rest of Europe
Market in Asia-Pacific	China India Japan South Korea Rest of Asia-Pacific
Market in Latin America	Argentina Brazil
Market in Middle East and North Africa	Israel Saudi Arabia United Arab Emirates Rest of Middle East and North Africa

Pay Only for What You Need – The Best Way to Optimize

The growing demand for mRNA as a drug agent, lack of manufacturing capabilities and the need for independent geographical mRNA therapeutics supply chain has prompted the mRNA drug production market players to outsource various operations involved in mRNA synthesis.

Industry Experts on mRNA Manufacturing Industry Outlook

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

Chief Executive Officer, Mid-sized Organization, Belgium
Chief Commercial Officer, Mid-sized Organization, France
Business Development Manager, Mid-sized Organization, Spain
Team Leader, Large Organization, South Korea

In addition, the market report includes transcripts of the following other third-party discussions:

Scientist in Nucleic Acid Therapeutics, Very Large Organization, United States
Senior Product Manager, Very Large Organization, United States
NEB RNA Research Senior Scientist, Large Organization, United States
Professor and Director of the BASE facility and, Associate Professor and Deputy Director of the BASE facility, Vert Large Organization, Australia

mRNA synthesis and manufacturing domain will mark a turning point in 2025. Team Leader of a large organization in South Korea states, “More than 90% of the companies prefer to outsource the mRNA manufacturing operations to third party service providers.”

Market Share by Type of Product: Active Pharmaceutical Ingredients Sub-segment Holds the Largest Market Share

According to our projections, in 2026, the active pharmaceutical ingredients sub-segment is likely to capture majority (>60%) of the mRNA synthesis and manufacturing market share.

This is due to the fact that active pharmaceutical ingredients serve as a fundamental component of any therapeutic / vaccine, thereby affecting the overall efficacy and safety of the product.

Market Share by Scale of Operation: Commercial Scale Sub-segment Hold the Largest Market Share

In the current year, commercial scale sub-segment occupies the highest market share (>85%) as per mRNA synthesis and manufacturing market report, given the fact that a large number of mRNA-based therapeutics and vaccines are currently commercialized.

Further, the market for preclinical and clinical scale is likely to witness a moderate increase, growing at a CAGR of 3.4% during the forecast period. Extensive research and development in this domain are fueling the growth in preclinical and clinical sector, due to which a rapid increase in the development of mRNA-based products has been witnessed. Moreover, the companies are focused on scale-up of mRNA manufacturing facilities to support operations across various scales.

Market Share by Synthesis and Manufacturing Activities: Contract Manufacturing Sub-segment Dominates the Market

Currently, the contract manufacturing sub-segment occupies the highest market share (~60%) as per our market report. This dominance is primarily driven by the complexity of mRNA production, which demands specialized expertise and often relies on third-party service providers.

Further, the market is likely to witness a substantial increase in the share of in-house manufacturing sub-segment, growing at a CAGR of 7.5% during the forecast period. This is because of growing emphasis on the safety and efficacy of mRNA-based therapeutics, which is encouraging researchers and drug developers to strengthen their in-house capabilities for producing high-quality mRNA.

Market Share by Indication Type: COVID-Indication Sub-segment Holds the Largest Share

In the current year, the COVID indication sub-segment occupies the highest market share (95%) as per mRNA synthesis and manufacturing market analysis. This is due to the fact that mRNA-based products can instruct cells to produce specific pathogen proteins, which in turn trigger a strong and targeted immune response without exposing the individual to the actual pathogen.

Further, the market is likely to witness a substantial increase in the share of non-COVID indications, growing at a CAGR of 37.5% during the forecast period. This is a result of several advancements that are being made in this domain to develop mRNA-based products for other therapeutic indications, including oncological disorders, rare disorders and genetic disorders.

Market Share by Therapeutic Area: Focus on Infectious Disease mRNA therapies

In 2026, the infectious diseases sub-segment occupies the highest market share (~95%), given the fact that mRNA therapeutics and vaccines showcased significant success in combating the COVID-19 pandemic.

Further, the market is likely to witness a significant oncology mRNA therapy manufacturing, with 60.7% mRNA synthesis and manufacturing market growth, owing to the increasing prevalence of cancer and a dire need to develop novel therapeutic options to treat oncological disorders efficiently.

Market Share by Application Area: mRNA Vaccines Sub-segment Holds the Largest Share

In 2026, the market is anticipated to be solely driven by mRNA vaccines sub-segment as per mRNA synthesis and manufacturing market forecast, given their proven clinical success, broad preventive applications and flexible nature.

Further, the market is likely to witness a substantial increase in the share of mRNA therapeutics, growing at a CAGR of 61.1% during the forecast period. This is because of their rapidly expanding therapeutic applications for therapeutic areas such as oncological, genetic, autoimmune and cardiovascular disorders, thus generating a strong clinical momentum for mRNA therapeutics.

Your Business is Unique – Why Shouldn’t Your Report Be?

Market Share by Geographical Regions: North America to Propel in the mRNA Synthesis and Manufacturing Sector in the Coming Years

As per our mRNA synthesis and manufacturing market trends, North America is likely to capture majority share (>40%) of the market. Furthermore, the market in North America is expected to grow at a CAGR of 6.6%, during the forecast period.

This is because of the advanced healthcare infrastructure in North America, enabling several players in the industry to conduct extensive research and develop novel mRNA modalities for a wide array of therapeutic indications.

mRNA Synthesis and Manufacturing Market: Report Deliverables

Report Deliverables	Details
Excel Data Packs (Complimentary)	Market Landscape (mRNA custom synthesis service providers) Market Landscape (mRNA contract manufacturing service providers) Market Landscape (mRNA synthesis kits) Company Competitiveness Analysis (mRNA custom synthesis service providers) Company Competitiveness Analysis (mRNA contract manufacturing service providers) Product Competitiveness Analysis (mRNA synthesis kits) Partnerships and Collaborations Likely Partner Analysis Big Player Initiatives Market Forecast and Opportunity Analysis
Key mRNA Synthesis and Manufacturing Companies Profiled	Aldevron APExBIO Aurigene Pharmaceutical Services BioCell Biomay BioNTech Biorbyt CELLSCRIPT Creative Biogene Curia Eurogentec GenScript eJena Bioscience Lonza Merck Porton Advanced Revolution Biotechnology Samsung Biologics ST Pharm Thermo Fisher Scientific TriLink BioTechnologies Vernal Biosciences WuXi Biologics YXgene (Full list of ~120 companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

mRNA Synthesis and Manufacturing Market Key Takeaways

The “mRNA Synthesis and Manufacturing Market (4th Edition): Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape of mRNA custom synthesis service providers, mRNA contract manufacturing service providers and mRNA synthesis kits along with their respective company competitiveness and product competitiveness analyses, partnerships and collaborations, likely partner analysis, big player initiatives and market size and future opportunities within the mRNA synthesis and manufacturing industry.

mRNA Market Competitive Landscape: mRNA Custom Synthesis Service Providers

Presently, close to 55 service providers are engaged in offering services for custom synthesis of mRNA. Of these, close to 40% of the companies have been established post-2011 indicating the growing interest of stakeholders in this domain. Notable examples of companies (established post- 2011, in alphabetical order) include APExBIO, BASE Facility, Click Biosystems and YXgene.

Further, about 60% of the players are headquartered in North America, given the more favorable and streamlined regulatory environment related to the approval of drugs across the region, allowing companies to operate with fewer barriers, compared to other regions.

Want Information on Specific Region / Segment?

Competitive Landscape of mRNA Contract Manufacturing Service Providers

The mRNA contract manufacturing service providers landscape features close to 45 players having expertise in providing contract services for the synthesis and manufacturing of mRNA. The market landscape is well-fragmented, featuring the presence of small, mid-sized, large, and very large companies.

Interestingly, majority (~60%) of the players offer manufacturing services for both drug substance and drug product. This integrated approach streamlines the overall drug development and manufacturing process for the clients, thereby reducing the risk of unwanted impurities and inconsistencies.

Market Size Analysis: What is the Opportunity for the mRNA Synthesis and Manufacturing?

The global mRNA synthesis and manufacturing market size is around $ 0.56 billion in 2026. In terms of the scale of operation, commercial scale sub-segment holds the largest share of the overall market owing to the fact that currently, a large number of mRNA therapeutics and vaccines are receiving regulatory approvals.

Further, the market size for preclinical and clinical scale is likely to grow at a relatively higher CAGR of 3.4% during the forecast period. The ability for mRNA therapeutics and vaccines to effectively target a wide array of disorders is targeting the growth of this sub-segment.

Regional Analysis: Which Region Holds the Largest mRNA Synthesis and Manufacturing Market Share?

North America is Leading the Market

North American companies are likely to dominate the market in 2035, owing to the robust research and development activities, coupled with the increasing adoption of mRNA therapeutics and growing mRNA vaccine manufacturing market trends within this region. Further, this trend is unlikely to change during the forecast period, with the market in North America growing at a higher CAGR of 6.6%.

What are the Key Drivers of mRNA Synthesis and Manufacturing Market?

The market is experiencing steady growth, primarily driven by the increasing extent of outsourcing in this domain owing to the growing need for specialized expertise, scalable production process, and robust infrastructure. Additionally, the rapid expansion of therapeutic applications, driven by the adaptability of mRNA technology and their potential to produce any protein in vivo and in vitro has accelerated the market growth.

Key Market Trends in mRNA Synthesis and Manufacturing Market

Rising Partnerships and Collaborations Amongst the mRNA Synthesis and Manufacturing Companies to Foster Progress and Innovation in Expanding their Capabilities

Players engaged in the mRNA synthesis and manufacturing domain have forged several partnerships with other stakeholders to enhance their respective service and kit portfolios. Close to 50% of the partnerships in this domain were inked in the last three years. Both international and local stakeholders have signed numerous agreements focused on mRNA synthesis and manufacturing across various regions; however, the activity was observed to be primarily concentrated in the US. Within this workflow, cell free protein expression produces proteins without living cells, shortening construct-to-protein and screening workflows.

Increase in Big Player Initiatives Reflects the Rising Interest of Companies in mRNA Synthesis and Manufacturing

Big players in this domain have strategically entered into several partnerships, acquired other firms, raised several fundings and expanded their capabilities in order to stay at the forefront of this domain. Notably, close to 20% of the initiatives in this domain were undertaken in the last two years. Of these, maximum initiatives were undertaken by big players in the year 2022; this is because of the increased demand of mRNA for production of COVID-related vaccines and therapeutics. Moreover, the players are meticulously focused on complying with the regulatory landscape for mRNA production.

mRNA Synthesis and Manufacturing Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the mRNA synthesis and manufacturing industry, across different geographies. Amongst other elements, the market report includes:

An Infographic Executive Summary
Market Landscape of mRNA Custom Synthesis Service Providers
Company Competitiveness Analysis of mRNA Custom Synthesis Service Providers
Market Landscape of mRNA Contract Manufacturing Service Providers
Company Competitiveness Analysis of mRNA Contract Manufacturing Service Providers
Market Landscape of mRNA Synthesis Kits
Product Competitiveness Analysis of mRNA Synthesis Kits
Partnerships and Collaborations
Likely Partner Analysis
Big Pharma Initiatives
Market Forecast and Opportunity Analysis

Table of Content

+ 1. BACKGROUND

1.1. Context

1.2. Project Objectives

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations on the Industry

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape

5.2. Executive Summary: Market Trends

5.3. Executive Summary: Market Forecast and Opportunity Analysis

+ 6. INTRODUCTION

6.1. Overview of mRNA

6.2. Structure of mRNA

6.3. Evolution of mRNA Vaccines

6.4. Types of mRNA Synthesis Processes

6.4.1. Chemical Synthesis of mRNA

6.4.2. In vitro Synthesis of mRNA

6.5. Applications of mRNA

6.6. Challenges Associated with mRNA Synthesis

6.7. Commonly Outsourced mRNA Manufacturing Operations

6.8. Advantages of Outsourcing Manufacturing Operations

6.9. Conclusion

+ 7. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: MARKET LANDSCAPE

7.1. Overview of mRNA Custom Synthesis Service Providers

7.1.1. Analysis by Year of Establishment

7.1.2. Analysis by Company Size

7.1.3. Analysis by Location of Headquarters

7.1.4. Analysis by Company Size and Location of Headquarters

7.1.5. Analysis by Type of Service Offered

7.1.6. Analysis by Type of Starting Material

7.1.7. Analysis by Structural Modification

7.1.8. Analysis by Type of Purification Method

7.1.9. Analysis by Scale of Operation

7.1.10. Analysis by Application Area

7.1.11. Analysis by GMP Compliance

+ 8. COMPANY COMPETITVENESS ANALYSIS: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

8.1. Methodology and Key Parameters

8.2. Scoring Criteria

8.3. Overview of Peer Groups

8.4. Company Competitiveness Analysis

8.4.1. Competitiveness Analysis of Service Providers headquartered in North America: 2D Dot Plot

8.4.2. Leading Service Providers headquartered in North America: Spider Web Analysis

8.4.3. Competitiveness Analysis of Service Providers headquartered in Europe: 2D Dot Plot

8.4.4. Leading Service Providers headquartered in Europe: Spider Web Analysis

8.4.5. Competitiveness Analysis of Service Providers headquartered in Asia-Pacific: 2D Dot Plot

8.4.6. Leading Service Providers headquartered in Asia-Pacific: Spider Web Analysis

+ 9. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE

9.1. Overview of mRNA Contract Manufacturing Service Providers

9.1.1. Analysis by Year of Establishment

9.1.2. Analysis by Company Size

9.1.3. Analysis by Location of Headquarters (Region)

9.1.4. Analysis by Location of Headquarters (Country)

9.1.5. Analysis by Location of Manufacturing Facilities

9.1.6. Analysis by Type of Product Manufactured

9.1.7. Analysis by GMP Compliance

9.1.8. Analysis by Scale of Operation

9.1.9. Analysis by Type of Additional Services Offered

+ 10. COMPANY COMPETITVENESS ANALYSIS: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

10.1. Methodology and Key Parameters

10.2. Scoring Criteria

10.3. Overview of Peer Groups

10.4. Company Competitiveness Analysis

10.4.1. Competitiveness Analysis of Service Providers headquartered in North America: 2D Dot Plot

10.4.2. Leading Service Providers headquartered in North America: Spider Web Analysis

10.4.3. Competitiveness Analysis of Service Providers headquartered in Europe: 2D Dot Plot

10.4.4. Leading Service Providers headquartered in Europe: Spider Web Analysis

10.4.5. Competitiveness Analysis of Service Providers headquartered in Asia-Pacific: 2D Dot Plot

10.4.6. Leading Service Providers headquartered in Asia-Pacific: Spider Web Analysis

+ 11. mRNA SYNTHESIS KITS: MARKET LANDSCAPE

11.1. Overview of mRNA Synthesis Kits

11.1.1. Analysis by Kit Components

11.1.2. Analysis by Type of Enzyme

11.1.3. Analysis by Type of Enzyme Mix Used

11.1.4. Analysis by mRNA Component Modified

11.1.5. Analysis by Number of Reactions

11.1.6. Analysis by Yield per Reaction

11.1.7. Analysis by Reaction Run-time

11.1.8. Analysis by Shelf Life

11.2. mRNA Synthesis Kits: Developers Landscape

11.2.1. Analysis by Year of Establishment

11.2.2. Analysis by Company Size

11.2.3. Analysis by Location of Headquarters

11.2.4. Most Active Players: Analysis by Number of Kits Developed

+ 12. PRODUCT COMPETITVENESS ANALYSIS: mRNA SYNTHESIS KITS

12.1. Methodology and Key Parameters

12.2. Scoring Criteria

12.3. Leading mRNA Synthesis Kits: 2D Dot Plot

+ 13. COMPANY PROFILES: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

13.1. Methodology

13.2. Aldevron

13.2.1. Company Details

13.2.2. Service Portfolio

13.2.3. Financial Information

13.2.4. Future Outlook

13.3. Thermo Fischer Scientific

13.4. Revolution Biomanufacturing

13.5. BioNTech

13.6. Eurogentec

13.7. Biocell

13.8. YXgene

13.9. Aurigene Pharmaceutical Services

13.10. Biomay

13.11. GenScript

13.12. Trilink Biotechnologies

+ 14. COMPANY PROFILES: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

14.1. Methodology

14.2. Curia

14.2.1. Company Details

14.2.2. Service Portfolio

14.2.3. Financial Information

14.2.4. Future Outlook

14.3. Lonza

14.4. Merck

14.5. Porton Advanced

14.6. Samsung Biologics

14.7. ST Pharm

14.8. Vernal Biosciences

14.9. Wuxi Biologics

+ 15. COMPANY PROFILES: mRNA SYNTHESIS KITS

15.1. Methodology

15.2. APExBIO

15.2.1. Company Details

15.2.2. mRNA Synthesis Kits Portfolio

15.3. Biorbyt

15.4. Cell Script

15.5. Creative Biogene

15.6. Jena Bioscience

15.7. Thermo Fischer Scientific

+ 16. PARTNERSHIPS AND COLLABORATIONS

16.1. Partnership Models

16.2. mRNA Synthesis and Manufacturing Market: Partnerships and Collaborations

16.2.1. Analysis by Year of Partnership

16.2.2. Analysis by Type of Partnership

16.2.3. Analysis by Year and Type of Partnership

16.2.4. Analysis by Type of Partner

16.2.5. Analysis by Type of Pharmaceutical

16.2.6. Analysis by Type of Drug Product

16.2.7. Most Active Players: Analysis by Number of Partnerships

16.2.8. Analysis by Geography

16.2.8.1. Local and International Deals

16.2.8.2. Intracontinental and Intercontinental Deals

+ 17. LIKELY PARTNER ANALYSIS

17.1. mRNA Synthesis and Manufacturing Market: Likely Partner Analysis

17.2. Methodology and Key Parameters

17.3. Scoring Criteria

17.4. mRNA Drug Developers: Likely Partners based in North America

17.4.1. mRNA Drug Developers: Most Likely Partners based in North America

17.5. mRNA Drug Developers: Likely Partners based in Europe

17.5.1. mRNA Drug Developers: Most Likely Partners based in Europe

17.6. mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World

17.6.1. mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World

+ 18. BIG PLAYER INITIATIVES

18.1. Methodology

18.2. Key Initiatives Analyzed

18.3. mRNA Synthesis and Manufacturing Market: Big Player Initiatives

18.3.1. Analysis by Year of Initiative

18.3.2. Analysis by Type of Initiative

18.3.3. Analysis by Year and Type of Initiative

18.3.4. Big Players: Analysis by Number of Initiatives

18.3.5. Big Players: Analysis by Type of Initiative

18.3.6. Analysis by Type of Pharmaceutical

18.3.7. Analysis by Therapeutic Area

18.3.8. Big Players: Analysis by Number of Partnerships

18.3.9. Analysis by Type of Partnership

18.3.10. Big Players: Analysis by Number of Expansions

18.3.11. Analysis by Type of Expansion

18.3.12. Big Players: Analysis by Region of Expansion

+ 19. MARKET IMPACT ANALYSIS

19.1. Market Drivers

19.2. Market Restraints

19.3. Market Opportunities

19.4. Market Challenges

+ 20. GLOBAL mRNA SYNTHESIS AND MANUFACTURING MARKET

20.1. Key Assumptions and Methodology

20.2. Global mRNA Synthesis and Manufacturing Market: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

20.2.1. Scenario Analysis

20.2.1.1. Conservative Scenario

20.2.1.2. Optimistic Scenario

20.3. Comparison with Previous Edition

20.4. Key Market Segmentations

+ 21. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY TYPE OF PRODUCT

21.1. Methodology

21.2. mRNA Synthesis and Manufacturing Market: Distribution by Type of Product

21.2.1. mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

21.2.2. mRNA Synthesis and Manufacturing Market for Finished Dose Formulations: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 22. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY SCALE OF OPERATION

22.1. Methodology

22.2. mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation

22.2.1. mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

22.2.2. mRNA Synthesis and Manufacturing Market for Commercial Scale: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 23. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY SYNTHESIS AND MANUFACTURING ACTIVITY

23.1. Methodology

23.2. mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity

23.2.1. mRNA Synthesis and Manufacturing Market for Contract Manufacturing: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

23.2.2. mRNA Synthesis and Manufacturing Market for In-house Manufacturing: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 24. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY INDICATION TYPE

24.1. Methodology

24.2. mRNA Synthesis and Manufacturing Market: Distribution by Indication Type

24.2.1. mRNA Synthesis and Manufacturing Market for COVID Indications: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

24.2.2. mRNA Synthesis and Manufacturing Market for Non-COVID Indications: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 25. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY THERAPEUTIC AREA

25.1. Methodology

25.2. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area

25.2.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

25.2.2. mRNA Synthesis and Manufacturing Market for Oncological Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

25.2.3. mRNA Synthesis and Manufacturing Market for Other Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 26. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY APPLICATION AREA

26.1. Methodology

26.2. mRNA Synthesis and Manufacturing Market: Distribution by Application Area

26.2.1. mRNA Synthesis and Manufacturing Market for mRNA Vaccines: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

26.2.2. mRNA Synthesis and Manufacturing Market for mRNA Therapeutics: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 27. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

27.1. Methodology

27.2. mRNA Synthesis and Manufacturing Market: Distribution by Geographical Regions

27.2.1. mRNA Synthesis and Manufacturing Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.1.1. mRNA Synthesis and Manufacturing Market in the US: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.1.2. mRNA Synthesis and Manufacturing Market in Canada: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.2. mRNA Synthesis and Manufacturing Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.2.1. mRNA Synthesis and Manufacturing Market in Germany: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.2.2. mRNA Synthesis and Manufacturing Market in France: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.2.3. mRNA Synthesis and Manufacturing Market in the UK: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.2.4. mRNA Synthesis and Manufacturing Market in Italy: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.2.5. mRNA Synthesis and Manufacturing Market in Spain: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.2.6. mRNA Synthesis and Manufacturing Market in Rest of Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.3.1. mRNA Synthesis and Manufacturing Market in China: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.3.2. mRNA Synthesis and Manufacturing Market in India: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.3.3. mRNA Synthesis and Manufacturing Market in Japan: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.3.4. mRNA Synthesis and Manufacturing Market in South Korea: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.3.5. mRNA Synthesis and Manufacturing Market in Rest of Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.4. mRNA Synthesis and Manufacturing Market in Latin America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.4.1. mRNA Synthesis and Manufacturing Market in Brazil: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.4.2. mRNA Synthesis and Manufacturing Market in Argentina: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.5.1. mRNA Synthesis and Manufacturing Market in Saudi Arabia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.5.2. mRNA Synthesis and Manufacturing Market in Israel: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.5.3. mRNA Synthesis and Manufacturing Market in United Arab Emirates: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27.2.5.4. mRNA Synthesis and Manufacturing Market in Rest of Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 28. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

28.1. mRNA Synthesis and Manufacturing Market in North America: Distribution by Type of Product

28.1.1. mRNA Synthesis and Manufacturing Market in North America for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.1.2. mRNA Synthesis and Manufacturing Market in North America for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.2. mRNA Synthesis and Manufacturing Market in North America: Distribution by Scale of Operation

28.2.1. mRNA Synthesis and Manufacturing Market in North America for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.2.2. mRNA Synthesis and Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.3. mRNA Synthesis and Manufacturing Market in North America: Distribution by Synthesis and Manufacturing Activity

28.3.1. mRNA Synthesis and Manufacturing Market in North America for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.3.2. mRNA Synthesis and Manufacturing Market in North America for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.4. mRNA Synthesis and Manufacturing Market in North America: Distribution by Indication Type

28.4.1. mRNA Synthesis and Manufacturing Market in North America for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.4.2. mRNA Synthesis and Manufacturing Market in North America for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.5. mRNA Synthesis and Manufacturing Market in North America: Distribution by Therapeutic Area

28.5.1. mRNA Synthesis and Manufacturing Market in North America for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.5.2. mRNA Synthesis and Manufacturing Market in North America for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.5.3. mRNA Synthesis and Manufacturing Market in North America for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.6. mRNA Synthesis and Manufacturing Market in North America: Distribution by Application Area

28.6.1. mRNA Synthesis and Manufacturing Market in North America for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28.6.2. mRNA Synthesis and Manufacturing Market in North America for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 29. MARKET OPPORTUNITY ANALYSIS: EUROPE

29.1. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Type of Product

29.1.1. mRNA Synthesis and Manufacturing Market in Europe for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.1.2. mRNA Synthesis and Manufacturing Market in Europe for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.2. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Scale of Operation

29.2.1. mRNA Synthesis and Manufacturing Market in Europe for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.2.2. mRNA Synthesis and Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.3. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Synthesis and Manufacturing Activity

29.3.1. mRNA Synthesis and Manufacturing Market in Europe for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.3.2. mRNA Synthesis and Manufacturing Market in Europe for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.4. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Indication Type

29.4.1. mRNA Synthesis and Manufacturing Market in Europe for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.4.2. mRNA Synthesis and Manufacturing Market in Europe for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.5. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Therapeutic Area

29.5.1. mRNA Synthesis and Manufacturing Market in Europe for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.5.2. mRNA Synthesis and Manufacturing Market in Europe for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.5.3. mRNA Synthesis and Manufacturing Market in Europe for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.6. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Application Area

29.6.1. mRNA Synthesis and Manufacturing Market in Europe for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29.6.2. mRNA Synthesis and Manufacturing Market in Europe for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 30. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

30.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Type of Product

30.1.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.1.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation

30.2.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.2.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Synthesis and Manufacturing Activity

30.3.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.3.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.4. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Indication Type

30.4.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.4.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.5. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area

30.5.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.5.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.5.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.6. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Application Area

30.6.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30.6.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 31. MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

31.1. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Type of Product

31.1.1. mRNA Synthesis and Manufacturing Market in Latin America for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.1.2. mRNA Synthesis and Manufacturing Market in Latin America for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.2. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Scale of Operation

31.2.1. mRNA Synthesis and Manufacturing Market in Latin America for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.2.2. mRNA Synthesis and Manufacturing Market in Latin America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.3. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Synthesis and Manufacturing Activity

31.3.1. mRNA Synthesis and Manufacturing Market in Latin America for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.3.2. mRNA Synthesis and Manufacturing Market in Latin America for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.4. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Indication Type

31.4.1. mRNA Synthesis and Manufacturing Market in Latin America for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.4.2. mRNA Synthesis and Manufacturing Market in Latin America for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.5. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Therapeutic Area

31.5.1. mRNA Synthesis and Manufacturing Market in Latin America for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.5.2. mRNA Synthesis and Manufacturing Market in Latin America for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.5.3. mRNA Synthesis and Manufacturing Market in Latin America for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.6. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Application Area

31.6.1. mRNA Synthesis and Manufacturing Market in Latin America for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31.6.2. mRNA Synthesis and Manufacturing Market in Latin America for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ 32. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

32.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Type of Product

32.1.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.1.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Scale of Operation

32.2.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.2.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.3. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Synthesis and Manufacturing Activity

32.3.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.3.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.4. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Indication Type

32.4.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.4.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area

32.5.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.5.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.5.3. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.6. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Application Area

32.6.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32.6.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

**Detailed information on Chapter 28 to 32 is available in the Excel Data Packs shared along with the report**

+ 33. CONCLUDING INSIGHTS

+ 34. EXECUTIVE INSIGHTS

+ 35. APPENDIX I: TABULATED DATA

+ 36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Market Assessment Framework

Figure 4.1 Lessons Learnt from Past Recessions

Figure 5.1 Executive Summary: Market Landscape

Figure 5.2 Executive Summary: Market Trends

Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis

Figure 6.1 Structure of mRNA

Figure 6.2 Evolution of mRNA Vaccines

Figure 6.3 Chemical Synthesis

Figure 6.4 In-vitro Synthesis

Figure 6.5 Applications of mRNA

Figure 6.6 Advantages of Outsourcing Manufacturing Operations

Figure 7.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment

Figure 7.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size

Figure 7.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters

Figure 7.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters

Figure 7.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered

Figure 7.6 mRNA Custom Synthesis Service Providers: Distribution by Starting Material

Figure 7.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification

Figure 7.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method

Figure 7.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation

Figure 7.10 mRNA Custom Synthesis Service Providers: Distribution by Application Area

Figure 7.11 mRNA Custom Synthesis Service Providers: Distribution by GMP Compliance

Figure 8.1 Company Competitiveness Analysis: Service Providers based in North America

Figure 8.2 Company Competitiveness Analysis: Service Providers based in Europe

Figure 8.3 Company Competitiveness Analysis: Service Providers based in Asia-Pacific

Figure 9.1 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment

Figure 9.2 mRNA Contract Manufacturing Service Providers: Distribution by Company Size

Figure 9.3 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Region)

Figure 9.4 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Country)

Figure 9.5 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities

Figure 9.6 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured

Figure 9.7 mRNA Contract Manufacturing Service Providers: Distribution by GMP Compliance

Figure 9.8 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation

Figure 9.9 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services Offered

Figure 10.1 Company Competitiveness Analysis: Service Providers based in North America

Figure 10.2 Company Competitiveness Analysis: Service Providers based in Europe

Figure 10.3 Company Competitiveness Analysis: Service Providers based in Asia-Pacific

Figure 11.1 mRNA Synthesis Kits: Distribution by Kit Components

Figure 11.2 mRNA Synthesis Kits: Distribution by Type of Enzyme

Figure 11.3 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used

Figure 11.4 mRNA Synthesis Kits: Distribution by mRNA Component Modified

Figure 11.5 mRNA Synthesis Kits: Distribution by Number of Reactions

Figure 11.6 mRNA Synthesis Kits: Distribution by Yield Per Reaction

Figure 11.7 mRNA Synthesis Kits: Distribution by Reaction Run Time

Figure 11.8 mRNA Synthesis Kits: Distribution by Shelf Life

Figure 11.9 mRNA Synthesis Kit Providers: Distribution by Year of Establishment

Figure 11.10 mRNA Synthesis Kit Providers: Distribution by Company Size

Figure 11.11 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters

Figure 11.12 Most Active Players: Distribution by Number of Kits Developed

Figure 12.1 mRNA Synthesis Kits: 2D Dot Plot

Figure 13.1 Danaher: Annual Revenues, Since FY 2021 (USD Billion)

Figure 13.2 Thermo Fischer Scientific: Annual Revenues, Since FY 2021 (USD Billion)

Figure 13.3 BioNTech: Annual Revenues, Since FY 2021 (EUR Billion)

Figure 13.4 Eurogentec: Annual Revenues, Since FY 2021 (JPY Billion)

Figure 14.1 Lonza: Annual Revenues, Since FY 2021 (CHF Billion)

Figure 14.2 Merck: Annual Revenues, Since FY 2021 (EUR Billion)

Figure 14.3 Samsung Biologics: Annual Revenues, Since FY 2021 (KRW Trillion)

Figure 14.4 ST Pharm: Annual Revenues, Since FY 2021 (KRW Billion)

Figure 14.5 Wuxi Biologics: Annual Revenues, Since FY 2020 (RMB Billion)

Figure 16.1 Partnerships and Collaborations: Distribution by Year of Partnership

Figure 16.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 16.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Figure 16.4 Partnerships and Collaborations: Distribution by Type of Partner

Figure 16.5 Partnerships and Collaborations: Distribution by Type of Pharmaceutical

Figure 16.6 Partnerships and Collaborations: Distribution by Type of Drug Product

Figure 16.7 Most Active Players: Distribution by Number of Partnerships

Figure 16.8 Partnerships and Collaborations: Local and International Deals

Figure 16.9 Partnerships and Collaborations: Intercontinental and Intracontinental Deals

Figure 18.1 Big Player Initiatives: Distribution by Year of Initiative

Figure 18.2 Big Player Initiatives: Distribution by Type of Initiative

Figure 18.3 Big Player Initiatives: Distribution by Year and Type of Initiative

Figure 18.4 Big Player Initiatives: Distribution of Player by Number of Initiatives

Figure 18.5 Big Player Initiatives: Distribution of Player by Type of Initiative

Figure 18.6 Big Player Initiatives: Distribution by Type of Pharmaceutical

Figure 18.7 Big Player Initiatives: Distribution by Therapeutic Area

Figure 18.8 Big Player Initiatives: Distribution of Player by Number of Partnerships

Figure 18.9 Big Player Initiatives: Distribution by Type of Partnership

Figure 18.10 Big Player Initiatives: Distribution of Player by Number of Expansions

Figure 18.11 Big Player Initiatives: Distribution by Type of Expansion

Figure 18.12 Big Player Initiatives: Distribution of Player by Region of Expansion

Figure 19.1 Market Trends and Outlook: Market Drivers

Figure 19.2 Market Trends and Outlook: Market Restraints

Figure 19.3 Market Trends and Outlook: Market Opportunities

Figure 19.4 Market Trends and Outlook: Market Challenges

Figure 20.1 Global mRNA Synthesis and Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 20.2 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario

Figure 20.3 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario

Figure 21.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product

Figure 21.2 mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 21.3 mRNA Synthesis and Manufacturing Market for Finished Dose Formulations, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 22.1 mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation

Figure 22.2 mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 22.3 mRNA Synthesis and Manufacturing Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 23.1 mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity

Figure 23.2 mRNA Synthesis and Manufacturing Market for Commercial Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 23.3 mRNA Synthesis and Manufacturing Market for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 24.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Indication

Figure 24.2 mRNA Synthesis and Manufacturing Market for COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 24.3 mRNA Synthesis and Manufacturing Market for Non-COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 25.1 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area

Figure 25.2 mRNA Synthesis and Manufacturing Market for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 25.3 mRNA Synthesis and Manufacturing Market for Oncological Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 25.4 mRNA Synthesis and Manufacturing Market for Other Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 26.1 mRNA Synthesis and Manufacturing Market: Distribution by Application Area

Figure 26.2 mRNA Synthesis and Manufacturing Market for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 26.3 mRNA Synthesis and Manufacturing Market for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.1 mRNA Synthesis and Manufacturing Market: Distribution by Geographical Region

Figure 27.2 mRNA Synthesis and Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.3 mRNA Synthesis and Manufacturing Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.4 mRNA Synthesis and Manufacturing Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.5 mRNA Synthesis and Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.6 mRNA Synthesis and Manufacturing Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.7 mRNA Synthesis and Manufacturing Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.8 mRNA Synthesis and Manufacturing Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.9 mRNA Synthesis and Manufacturing Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.10 mRNA Synthesis and Manufacturing Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.11 mRNA Synthesis and Manufacturing Market in rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.12 mRNA Synthesis and Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.13 mRNA Synthesis and Manufacturing Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.14 mRNA Synthesis and Manufacturing Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.15 mRNA Synthesis and Manufacturing Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.16 mRNA Synthesis and Manufacturing Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.17 mRNA Synthesis and Manufacturing Market in rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.18 mRNA Synthesis and Manufacturing Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.19 mRNA Synthesis and Manufacturing Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.20 mRNA Synthesis and Manufacturing Market in Argentina, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.21 mRNA Synthesis and Manufacturing Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.22 mRNA Synthesis and Manufacturing Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.23 mRNA Synthesis and Manufacturing Market in Israel, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.24 mRNA Synthesis and Manufacturing Market in United Arab Emirates, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Figure 27.25 mRNA Synthesis and Manufacturing Market in rest of Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ List of Tables

Table 7.1 List of mRNA Custom Synthesis Service Providers

Table 9.1 List of mRNA Contract Manufacturing Service Providers

Table 11.1 List of mRNA Synthesis Kits

Table 11.2 List of mRNA Synthesis Kit Developers

Table 12.1 Aldevron: Service Portfolio

Table 12.2 Aldevron: Recent Developments and Future Outlook

Table 12.3 Thermo Fischer Scientific: Service Portfolio

Table 12.4 Thermo Fischer Scientific: Recent Developments and Future Outlook

Table 12.5 Revolution Biomanufacturing: Service Portfolio

Table 12.6 Revolution Biomanufacturing: Recent Developments and Future Outlook

Table 12.7 BioNTech: Service Portfolio

Table 12.8 BioNTech: Recent Developments and Future Outlook

Table 12.9 Eurogentec: Service Portfolio

Table 12.10 Eurogentec: Recent Developments and Future Outlook

Table 12.11 Biocell: Service Portfolio

Table 12.12 Biocell: Recent Developments and Future Outlook

Table 12.13 YXgene: Service Portfolio

Table 12.14 YXgene: Recent Developments and Future Outlook

Table 13.1 Curia: Service Portfolio

Table 13.2 Curia: Recent Developments and Future Outlook

Table 13.3 Lonza: Service Portfolio

Table 13.4 Lonza: Recent Developments and Future Outlook

Table 13.5 Merck: Service Portfolio

Table 13.6 Merck: Recent Developments and Future Outlook

Table 13.7 Porton Advanced: Service Portfolio

Table 13.8 Porton Advanced: Recent Developments and Future Outlook

Table 13.9 Samsung Biologics: Service Portfolio

Table 13.10 Samsung Biologics: Recent Developments and Future Outlook

Table 13.11 ST Pharm: Service Portfolio

Table 13.12 ST Pharm: Recent Developments and Future Outlook

Table 13.13 Vernal Biosciences: Service Portfolio

Table 13.14 Vernal Biosciences: Recent Developments and Future Outlook

Table 13.15 Wuxi Biologics: Service Portfolio

Table 13.16 Wuxi Biologics: Recent Developments and Future Outlook

Table 14.1 APExBIO: mRNA Synthesis Kits Portfolio

Table 14.2 Biorbyt: mRNA Synthesis Kits Portfolio

Table 14.3 Cell Script: mRNA Synthesis Kits Portfolio

Table 14.4 Creative Biogene: mRNA Synthesis Kits Portfolio

Table 14.5 Jena Bioscience: mRNA Synthesis Kits Portfolio

Table 14.6 Thermo Fischer Scientific: mRNA Synthesis Kits Portfolio

Table 15.1 mRNA Synthesis and Manufacturing: List of Partnerships and Collaborations, since 2019

Table 15.2 mRNA Synthesis and Manufacturing: Information on Location of Headquarters (Country / Region) and Type of Agreement (Intercontinental / Intracontinental)

Table 16.1 mRNA Drug Developers: Potential Strategic Partners in North America

Table 16.2 Most Likely Partner

Table 17.1 Big Player Initiatives: List of mRNA Synthesis and Manufacturing Focused Initiatives, since 2019

Table 35.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment

Table 35.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size

Table 35.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters

Table 35.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters

Table 35.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered

Table 35.6 mRNA Custom Synthesis Service Providers: Distribution by Starting Material

Table 35.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification

Table 35.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method

Table 35.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation

Table 35.10 mRNA Custom Synthesis Service Providers: Distribution by Application Area

Table 35.11 mRNA Custom Synthesis Service Providers: Distribution by GMP Compliance

Table 35.12 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment

Table 35.13 mRNA Contract Manufacturing Service Providers: Distribution by Company Size

Table 35.14 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Region)

Table 35.15 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Country)

Table 35.16 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities

Table 35.17 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured

Table 35.18 mRNA Contract Manufacturing Service Providers: Distribution by GMP Compliance

Table 35.19 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation

Table 35.20 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services Offered

Table 35.21 mRNA Synthesis Kits: Distribution by Kit Components

Table 35.22 mRNA Synthesis Kits: Distribution by Type of Enzyme

Table 35.23 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used

Table 35.24 mRNA Synthesis Kits: Distribution by mRNA Component Modified

Table 35.25 mRNA Synthesis Kits: Distribution by Number of Reactions

Table 35.26 mRNA Synthesis Kits: Distribution by Yield Per Reaction

Table 35.27 mRNA Synthesis Kits: Distribution by Reaction Run Time

Table 35.28 mRNA Synthesis Kits: Distribution by Shelf Life

Table 35.29 mRNA Synthesis Kit Providers: Distribution by Year of Establishment

Table 35.30 mRNA Synthesis Kit Providers: Distribution by Company Size

Table 35.31 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters

Table 35.32 Most Active Players: Distribution by Number of Kits Developed

Table 35.33 Danaher: Annual Revenues, Since FY 2021 (USD Billion)

Table 35.34 Thermo Fischer Scientific: Annual Revenues, Since FY 2021 (USD Billion)

Table 35.35 BioNTech: Annual Revenues, Since FY 2021 (EUR Billion)

Table 35.36 Kaneka: Annual Revenues, Since FY 2021 (JPY Billion)

Table 35.37 Lonza: Annual Revenues, Since FY 2021 (CHF Billion)

Table 35.38 Merck: Annual Revenues, Since FY 2021 (EUR Billion)

Table 35.39 Samsung Biologics: Annual Revenues, Since FY 2021 (KRW Trillion)

Table 35.40 ST Pharm: Annual Revenues, Since FY 2021 (KRW Billion)

Table 35.41 Wuxi Biologics: Annual Revenues, Since FY 2020 (RMB Billion)

Table 35.42 Partnerships and Collaborations: Distribution by Year of Partnership

Table 35.43 Partnerships and Collaborations: Distribution by Type of Partnership

Table 35.44 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Table 35.45 Partnerships and Collaborations: Distribution by Type of Partner

Table 35.46 Partnerships and Collaborations: Distribution by Type of Pharmaceutical

Table 35.47 Partnerships and Collaborations: Distribution by Type of Drug Product

Table 35.48 Most Active Players: Distribution by Number of Partnerships

Table 35.49 Partnerships and Collaborations: Local and International Deals

Table 35.50 Partnerships and Collaborations: Intercontinental and Intracontinental Deals

Table 35.51 Big Player Initiatives: Distribution by Year of Initiative

Table 35.52 Big Player Initiatives: Distribution by Type of Initiative

Table 35.53 Big Player Initiatives: Distribution by Year and Type of Initiative

Table 35.54 Big Player Initiatives: Distribution of Player by Number of Initiatives

Table 35.55 Big Player Initiatives: Distribution of Player by Type of Initiative

Table 35.56 Big Player Initiatives: Distribution by Type of Pharmaceutical

Table 35.57 Big Player Initiatives: Distribution by Therapeutic Area

Table 35.58 Big Player Initiatives: Distribution of Player by Number of Partnerships

Table 35.59 Big Player Initiatives: Distribution by Type of Partnership

Table 35.60 Big Player Initiatives: Distribution of Player by Number of Expansions

Table 35.61 Big Player Initiatives: Distribution by Type of Expansion

Table 35.62 Big Player Initiatives: Distribution of Player by Region of Expansion

Table 35.63 Global mRNA Synthesis and Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.64 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario

Table 35.65 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario

Table 35.66 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product

Table 35.67 mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.68 mRNA Synthesis and Manufacturing Market for Finished Dose Formulations, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.69 mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation

Table 35.70 mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.71 mRNA Synthesis and Manufacturing Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.72 mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity

Table 35.73 mRNA Synthesis and Manufacturing Market for Commercial Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.74 mRNA Synthesis and Manufacturing Market for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.75 mRNA Synthesis and Manufacturing Market: Distribution by Type of Indication

Table 35.76 mRNA Synthesis and Manufacturing Market for COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.77 mRNA Synthesis and Manufacturing Market for Non-COVID Indication, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.78 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area

Table 35.79 mRNA Synthesis and Manufacturing Market for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.80 mRNA Synthesis and Manufacturing Market for Oncological Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.81 mRNA Synthesis and Manufacturing Market for Other Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.82 mRNA Synthesis and Manufacturing Market: Distribution by Application Area

Table 35.83 mRNA Synthesis and Manufacturing Market for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.84 mRNA Synthesis and Manufacturing Market for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.85 mRNA Synthesis and Manufacturing Market: Distribution by Geographical Region

Table 35.86 mRNA Synthesis and Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.87 mRNA Synthesis and Manufacturing Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.88 mRNA Synthesis and Manufacturing Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.89 mRNA Synthesis and Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.90 mRNA Synthesis and Manufacturing Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.91 mRNA Synthesis and Manufacturing Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.92 mRNA Synthesis and Manufacturing Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.93 mRNA Synthesis and Manufacturing Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.94 mRNA Synthesis and Manufacturing Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.95 mRNA Synthesis and Manufacturing Market in rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.96 mRNA Synthesis and Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.97 mRNA Synthesis and Manufacturing Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.98 mRNA Synthesis and Manufacturing Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.99 mRNA Synthesis and Manufacturing Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.100 mRNA Synthesis and Manufacturing Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.101 mRNA Synthesis and Manufacturing Market in rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.102 mRNA Synthesis and Manufacturing Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.103 mRNA Synthesis and Manufacturing Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.104 mRNA Synthesis and Manufacturing Market in Argentina, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.105 mRNA Synthesis and Manufacturing Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.106 mRNA Synthesis and Manufacturing Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.107 mRNA Synthesis and Manufacturing Market in Israel, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.108 mRNA Synthesis and Manufacturing Market in United Arab Emirates, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

Table 35.109 mRNA Synthesis and Manufacturing Market in rest of Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

+ List of Companies and Organizations

Please reach out to our team for more details.

mRNA Synthesis and Manufacturing Market

Global mRNA Synthesis and Manufacturing Market Overview

mRNA Synthesis and Manufacturing Market: Report Attributes

Recent Developments in mRNA Synthesis and Manufacturing Market

mRNA Synthesis and Manufacturing Market Segmentation Insights

mRNA Synthesis and Manufacturing Market: Market Segmentation

Industry Experts on mRNA Manufacturing Industry Outlook

Market Share by Type of Product: Active Pharmaceutical Ingredients Sub-segment Holds the Largest Market Share

Market Share by Scale of Operation: Commercial Scale Sub-segment Hold the Largest Market Share

Market Share by Synthesis and Manufacturing Activities: Contract Manufacturing Sub-segment Dominates the Market

Market Share by Indication Type: COVID-Indication Sub-segment Holds the Largest Share

Market Share by Therapeutic Area: Focus on Infectious Disease mRNA therapies

Market Share by Application Area: mRNA Vaccines Sub-segment Holds the Largest Share

Market Share by Geographical Regions: North America to Propel in the mRNA Synthesis and Manufacturing Sector in the Coming Years

mRNA Synthesis and Manufacturing Market: Report Deliverables

mRNA Synthesis and Manufacturing Market Key Takeaways

mRNA Market Competitive Landscape: mRNA Custom Synthesis Service Providers

Competitive Landscape of mRNA Contract Manufacturing Service Providers

Market Size Analysis: What is the Opportunity for the mRNA Synthesis and Manufacturing?

Regional Analysis: Which Region Holds the Largest mRNA Synthesis and Manufacturing Market Share?

North America is Leading the Market

What are the Key Drivers of mRNA Synthesis and Manufacturing Market?

Key Market Trends in mRNA Synthesis and Manufacturing Market

Rising Partnerships and Collaborations Amongst the mRNA Synthesis and Manufacturing Companies to Foster Progress and Innovation in Expanding their Capabilities

Increase in Big Player Initiatives Reflects the Rising Interest of Companies in mRNA Synthesis and Manufacturing

mRNA Synthesis and Manufacturing Market Report Coverage

Table of Content

The Future of Autonomous Deliveries: Integrating Drones and Self-Driving Vehicles

Radiopharmaceutical Manufacturing: A Multi-Disciplinary Endeavour for Medical Imaging and Interventional Treatment

mRNA Synthesis and Manufacturing Market

Global mRNA Synthesis and Manufacturing Market Overview

mRNA Synthesis and Manufacturing Market: Report Attributes

Recent Developments in mRNA Synthesis and Manufacturing Market

mRNA Synthesis and Manufacturing Market Segmentation Insights

mRNA Synthesis and Manufacturing Market: Market Segmentation

Industry Experts on mRNA Manufacturing Industry Outlook

mRNA Synthesis and Manufacturing Market Share Insights

Market Share by Type of Product: Active Pharmaceutical Ingredients Sub-segment Holds the Largest Market Share

Market Share by Scale of Operation: Commercial Scale Sub-segment Hold the Largest Market Share

Market Share by Synthesis and Manufacturing Activities: Contract Manufacturing Sub-segment Dominates the Market

Market Share by Indication Type: COVID-Indication Sub-segment Holds the Largest Share

Market Share by Therapeutic Area: Focus on Infectious Disease mRNA therapies

Market Share by Application Area: mRNA Vaccines Sub-segment Holds the Largest Share

Market Share by Geographical Regions: North America to Propel in the mRNA Synthesis and Manufacturing Sector in the Coming Years

mRNA Synthesis and Manufacturing Market: Report Deliverables

mRNA Synthesis and Manufacturing Market Key Takeaways

mRNA Market Competitive Landscape: mRNA Custom Synthesis Service Providers

Competitive Landscape of mRNA Contract Manufacturing Service Providers

Market Size Analysis: What is the Opportunity for the mRNA Synthesis and Manufacturing?

Regional Analysis: Which Region Holds the Largest mRNA Synthesis and Manufacturing Market Share?

North America is Leading the Market

What are the Key Drivers of mRNA Synthesis and Manufacturing Market?

Key Market Trends in mRNA Synthesis and Manufacturing Market

Rising Partnerships and Collaborations Amongst the mRNA Synthesis and Manufacturing Companies to Foster Progress and Innovation in Expanding their Capabilities

Increase in Big Player Initiatives Reflects the Rising Interest of Companies in mRNA Synthesis and Manufacturing

mRNA Synthesis and Manufacturing Market Report Coverage

Table of Content

The Future of Autonomous Deliveries: Integrating Drones and Self-Driving Vehicles

Radiopharmaceutical Manufacturing: A Multi-Disciplinary Endeavour for Medical Imaging and Interventional Treatment